TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04894981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive condition (CAVE)
Description: Driving course with obstacles in a CAVE system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive condition (HMD)
Description: Driving course with obstacles with a virtual reality headset

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non Immersive condition (Screen alone)
Description: Driving course with obstacles on a screen with physical simulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non Immersive condition (Screen with physical simulator)
Description: Driving course with obstacles on a screen only
Study: NCT05639166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBIO123
Description: IBIO123 10 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT05161676

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone monoester
Description: Commercially available ketone supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo drink
Description: Isocaloric placebo
Study: NCT05438511

Intervention type: BEHAVIORAL
Intervention: Focus group
Description: A semi-structured focus group discussion guide will be developed with question probes that cover 1) contextual factors, 2) barriers to implementation, and 3) facilitators to implementation, with secondary probing questions.

Intervention type: BEHAVIORAL
Intervention: Organizational Readiness for Implementing Change
Description: measures the extent to which organizational members are prepared to implement organizational change. The ORIC tool asks participants to rate their level of agreement with 12 statements pertaining to organizational readiness for change (change commitment and change efficacy) on a 5-point Likert Scale.
Study: NCT06520839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg
Description: We will include in the study 90 patients with diabetes and erectile dysfunction. We will use the IIEF-5 questionnaire to confirm the diagnosis of erectile dysfunction. Patients between the ages of 40 and 65 who score 21 points or less on the IIEF-5 scale will be included in the study. Each patient will receive drug tadalafil 5 mg every day for three months.
Study: NCT05555433

Intervention type: OTHER
Intervention: NO INTERVENTION
Description: no intervention

Intervention type: OTHER
Intervention: NO INTERVENTION
Description: no intervention
Study: NCT06001736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contralateral C7 root transfer for the treatment of spastic hemiparesis.
Description: Performing surgery to transfer the C7 nerve to treat stroke patients experiencing spastic hemiparesis.
Study: NCT05555433

Intervention type: OTHER
Intervention: NO INTERVENTION
Description: no intervention
Study: NCT05944471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing breastfeeding support with Telehealth
Description: After discharge, training videos on the importance of breast milk and breastfeeding prepared in line with the literature and explained by experts, and written documents (e-brochure, plain text version of breastfeeding trainings) were sent to individual mothers once a week between 10.00-14.00 hours via telehealth application. At the same time intervals, visualised messages explaining breastfeeding and that breast milk is sufficient for the baby were sent via telehealth application five days a week. In addition, if the mothers requested at 10.00-17.00 on weekdays, they were given live support by the researcher for the issues they were curious about breastfeeding by calling the researcher via telehealth application.
Study: NCT06582303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality Game intervention plus conventional physical therapy
Description: The experimental group initially got VR intervention by playing all four easy-level games named hitting a rolling ball, grasping a balloon, swapping hands, and gripping twice for three minutes each during the first and second weeks. This group again underwent VR intervention by playing all four same games with a difficulty level twice 5 min duration for the third, fourth, fifth, and sixth weeks. The experimental group had an intervention of 24 sessions, lasting 4 days/week for a total of 6 weeks. During the first two weeks, patients received 24 minutes of VR hand games and 24 minutes of therapy sessions per day and for the next four weeks, this group received 40 minutes of VR hand games and 40 minutes of conventional therapy session per day. This group received conventional physical therapy that consists of range of motion, stretching, resistance, and strengthening exercises. At follow-up of two weeks this group only received conventional physical therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: The control group received conventional physical therapy, which consists of range of motion, stretching, resistance, and strengthening exercises by using powerweb, thera putty, and occupational therapy equipment. The CPT group had a conventional intervention of 24 sessions, lasting 4 days/week for a total of 6 weeks. The CPT group was given 48 minutes of conventional physical therapy sessions per day for weeks 1 and 2 followed by 80 minutes of conventional physical therapy sessions per day for the next 4 weeks. At follow-up of two weeks, this group also received conventional physical therapy.
Study: NCT04898699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UrSure Rapid Urine Tenofovir Test
Description: A point of care urine immunoassay to measure PrEP drug levels for adherence in participant urine samples over the preceding seven days will be done at all follow-up visits. At enrollment, study staff will explain the use of this experimental measurement of PrEP drug level in urine samples. Participants will receive results of the test at the same study visit during which it is performed.
Study: NCT05246982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07+HLX10+oxaliplatin+capecitabine
Description: HLX07 1500mg+HLX10 300mg+oxaliplatin 130mg/m2+capecitabine 1000mg/m2 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: HLX07 1500mg q3w
Study: NCT04898699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OraQuick Rapid HIV Self-test kit
Description: Participants will be provided with HIV self-testing kits to use at their discretion and, in case of multi-month dispensing, prior to start of new bottle of PrEP medication, in between study visits. HIV self-testing kits will be provided to confirm their HIV-negative status and make a connection between PrEP use and protection against HIV. Participants will receive detailed, interactive training on HIVST with pictorial elements, including instructions to contact study staff immediately in event of a reactive test for confirmation as per Kenya guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir (300mg)/Emtricitabine(200mg) [Truvada®]
Description: Information will be provided regarding dosing of PrEP medications, importance of daily adherence, importance of frequent HIV testing, and signs and symptoms of drug toxicity, acute HIV infection and STIs. An initial one-month supply (30 pills) of FTC/TDF will be given to all PrEP study participants. At the one-month study assessment, a two-month supply of daily oral FTC/TDF will be given to each participant, after HIV testing, assessment for acute HIV infection and review of side effects and adherence, following national guidelines and procedures for PrEP services. At Month 3 assessment, a three-month supply of oral FTC/TDF will be given.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2-way text message reminders
Description: All participants will receive weekly SMS visit reminders to support PrEP adherence. Participants will be asked at study enrollment for a primary contact telephone number and an alternate number for contact. Participants without cell phones will be provided an inexpensive cell phone (although cell phone ownership is very high in Kenya). Participants will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, use of HIV self-test kit, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with any questions, concerns or messages that they have for the study staff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV risk-reduction counseling
Description: All study participants will be provided with brief interactive counseling at each study visit, tailored to the results of their urine assay.
Study: NCT05236335

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: Commercially available ketone supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Isocaloric placebo
Study: NCT04966871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (7G8) for CHMI
Description: Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge (7G8) for CHMI
Description: Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (7G8) for CHMI
Description: Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge (7G8) for CHMI
Description: Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (7G8) for CHMI
Description: Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge (7G8) for CHMI
Description: Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: normal saline placebo control

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: normal saline placebo control

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: normal saline placebo control
Study: NCT06305117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distraction strategy
Description: Distraction strategy combining the use of virtual reality and music
Study: NCT06192069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustainable Heat Strain Prevention Program for Agricultural Elderly Workers (SHiP-AEW)
Description: The SHiP-AEW is a 4-week multifaceted intervention program focused on evidence-based heat strain prevention strategies for agricultural workers over 60 years old. Delivered through weekly 1-hour sessions, the program incorporates the following primary components:
Study: NCT05773053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium botulinum neurotoxin type A (150 kiloDalton \[kD\], free of complexing proteins) powder for solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium botulinum neurotoxin type A (150 kiloDalton \[kD\], free of complexing proteins) powder for solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium botulinum neurotoxin type A (150 kiloDalton \[kD\], free of complexing proteins) powder for solution for injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NT 201 Placebo
Description: NT 201 Matching-placebo.
Study: NCT06254131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron lozenge (Ondalenz ©)
Description: Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron IV
Description: Patients will receive 4 mg of ondansetron IV approximately 30 minutes before the end of surgery.
Study: NCT05517291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel-coated balloon angioplasty or bare mental stents implantation
Description: paticipants who enrolled in this study will received paclitaxel-coated balloon angioplasty plus bailout stenting or primary bare mental stents implantation randomly

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel-coated balloon angioplasty or bare mental stents implantation
Description: paticipants who enrolled in this study will received paclitaxel-coated balloon angioplasty plus bailout stenting or primary bare mental stents implantation randomly
Study: NCT04997577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory-cognitive training paradigm
Description: The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. A short-term memory component, in which listeners are asked to remember what a designated speaker said two sentences prior, was added to the auditory training paradigm to make the task more challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory training paradigm
Description: The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
Study: NCT05131555

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Placebo + exercise training.
Description: Oral placebo Exercise training: Interval-based cycling exercise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 blockade: H1 receptor antagonist + exercise training
Description: H1 blockade: oral blockade Exercise training: Interval-based cycling exercise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H2 Blockade: H2 receptor antagonist + exercise training
Description: H2 blockade: oral blockade Exercise training: Interval-based cycling exercise
Study: NCT03743532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette Switching
Description: Participants provided with e-cigarette device and nicotine pods and advised to switch from combustible cigarettes to e-cigarettes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette Switching
Description: Participants provided with e-cigarette device and nicotine pods and advised to switch from combustible cigarettes to e-cigarettes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Participants earned incentives for carbon monoxide-verified combustible cigarette abstinence.
Study: NCT06207721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycols
Description: Polyethylene Glycols syrup (0.7 g/kg daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycols
Description: Polyethylene Glycols syrup (0.7 g/kg daily)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy program
Description: The physical therapy program includes exercises and massage
Study: NCT05186116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Living donor liver transplant, Split liver transplant, RAPID, DDLT
Description: Transplantation of part of the liver from a living donor, or entire cadaveric graft
Study: NCT05489952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron sucrose and ferrous lactate
Description: The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge.
Study: NCT05230160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: Intermittent Fasting (IF) is a dietary intervention that involves periodic intervals of no or very limited energy intake. Fasting and feeding intervals vary and the practice of IF commonly consists of either a daily fast for 16 hours, a 24-hour fast on alternate days, or a fast two days per week on non-consecutive days.~For the study, the IF group will be asked to fast for 16 consecutive hours, 6 days per week. This means they will have an 8-hour eating window (e.g., eat from 10 a.m. to 6 p.m.) each day. They will be asked to eat the same types of food and the same amounts as usual, but only during the 8-hour eating window.
Study: NCT05805293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Velocity Nasal Insufflation Therapy
Description: Parameter settings for the HVNI apparatus are as follows:~1. The flow of HVNI will initially be set at 30-40 L/min, and inspiratory flow rate could be increased to 45-60 L/min.~2. FIO2 will be adjusted to maintain a SaO2 more than 90 % and relative humidity of 30-34%.~3. Temperature range of 35-37°C.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Ventilation
Description: Patients will be put on inspiratory/expiratory pressure 10/5 cmH2O (11). The inspiratory and expiratory pressures will be titrated with increments of 2 cmH2O based on improvement of oxygen saturation by continuous pulse oximetry and arterial blood gases values, alleviation of dyspnea and a decrease of respiratory rate and heart rate. The maximum allowed inspiratory pressure was 20 cm H2O. The maximum allowed expiratory pressure was 10 cm H2O.
Study: NCT06466954

Intervention type: OTHER
Intervention: Evaluating spinopelvic alignment parameters
Description: Evaluation of thoracic kyphosis, lumbar lordosis, pelvic tilt, and pelvic torsion

Intervention type: OTHER
Intervention: Evaluating spinopelvic alignment parameters
Description: Evaluation of thoracic kyphosis, lumbar lordosis, pelvic tilt, and pelvic torsion

Intervention type: OTHER
Intervention: Measuring uterine dimensions
Description: Measurement of corpus length, corpus width, cervix length, and cervix width

Intervention type: OTHER
Intervention: Measuring uterine dimensions
Description: Measurement of corpus length, corpus width, cervix length, and cervix width
Study: NCT06110338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo iv. once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo iv. once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo iv. once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo iv. once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo iv. once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo iv. once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo iv. once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355
Description: IBI355 iv. once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355
Description: IBI355 iv. once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355
Description: IBI355 iv. once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355
Description: IBI355 iv. once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355
Description: IBI355 iv. once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355
Description: IBI355 iv. once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI355
Description: IBI355 iv. once.
Study: NCT05741788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Various Stimulation Patterns
Description: Participants will undergo a structured optimization evaluating existing types of stimulation (tonic, burst, and multistim). Each participant will try out all types of available stimulation but be blinded to the type. Over the course of four months, each participant will evaluate each type of stimulation by reporting daily pain scores. Participants will follow up routinely to collect laboratory, behavioral, and survey responses to test for the feasibility of obtaining data explaining pain phenotype.
Study: NCT05755399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain imaging using transcranial focused ultrasound (tFUS)
Description: All enrolled patients will be imaged using the MRI as standard of care. The patient will additionally be imaged using the tFUS system, ICC HIFU Synthesizer. Total imaging time will be limited to 15 minutes. Following image acquisition by the ultrasound, the standard of care surgery will be performed.
Study: NCT06234683

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web-based educational video on pneumococcal vaccination
Description: Participants will receive a link to view a short video on pneumococcal vaccination.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reminder email to be vaccinated
Description: Participants will receive a reminder email to be vaccinated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reminder email to be vaccinated
Description: Participants will receive a reminder email to be vaccinated.